NEW YORK (GenomeWeb News) – Trovagene today said that it has entered into a memorandum of understanding with Strand Life Sciences, under which Strand will license and validate Trovagene's human papillomavirus urine test and high-risk HPV DNA assay.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: global genetic diversity map, and more.
The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.
In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."
Stat News reports that there's muted opposition to the Kuwaiti DNA database law.